

McCreadie Group Implements Investigational Drug Service Software, Vestigo®, at Roswell Park Cancer Institute

Pharmacy software solutions company helps leading cancer research institute streamline workflow and improve quality assurance.

Ann Arbor, Mich. (PRWEB) December 02, 2014 - McCreadie Group, Inc., a privately held pharmacy software solutions company headquartered in Ann Arbor, Mich., announces Roswell Park Cancer Institute (RPCI) as a new user of its web-based Investigational Drug Service (IDS) software, Vestigo®.

Vestigo® has set the industry standard for IDS automation by lending efficiencies to the workflow of investigational drug service operations while helping ensure that complex protocols are properly managed for consistency, safety and regulatory compliance. Launched in 2005, Vestigo® is used by many of the country's top research institutions, as well as several smaller research pharmacies.

RPCI, located in downtown Buffalo, N.Y., includes a medical research complex on its 28-acre campus. Since its founding in 1898 as the country's first cancer center, RPCI has held a leadership position in setting standards of cancer care, research and education.

"Accuracy in drug delivery and dose documentation are critical elements of clinical research, patient safety and care optimization. Integration of an electronic drug-accountability system into our investigational drug service is central to that effort," said Barbara Todaro, BS, PharmD, Director of the Investigational Drug Service at RPCI. "Today's technological tools bring new capabilities that we expect will streamline our workflow at the same time that they enhance our quality-assurance efforts."

Attention was recently drawn to the principles and practices of IDS by the Hematology/Oncology Pharmacy Association (HOPA) Best Practice Standards, announced in September 2014. The standards are directed at organizations managing clinical research in cancer patients, but apply to any clinical research involving medications.

"Vestigo® serves to help IDS comply with the HOPA Best Practice Standards in several areas, but is probably most directly relevant to its general best practice guideline of using computer software for investigational medication management," said Mike Schlesselman, PharmD, director of research products for McCreadie Group. "Vestigo® is proving itself in 50 research hospitals and cancer centers across the country every day. We are very pleased to add Roswell Park to our rapidly growing list of prestigious clients."

Vestigo® is used by 45 percent of all National Cancer Institute (NCI)-designated cancer centers and 70 percent of the top National Institutes of Health (NIH)-funded research institutions.

About McCreadie Group

The McCreadie Group, Inc. was founded in 2004 to provide software solutions for pharmacy applications in healthcare, research and educational settings. Our goal is to drive improvements in quality, efficiency, safety and compliance in the pharmacy profession by delivering innovative software and consultative support. To learn more about McCreadie Group and its products, visit <http://www.mccreadiegroup.com>.

About Roswell Park Cancer Institute

The mission of Roswell Park Cancer Institute (RPCI) is to understand, prevent and cure cancer. Founded in 1898, RPCI is one of the first cancer centers in the country to be named a National Cancer Institute-designated comprehensive cancer center, and remains the only facility with this designation in Upstate New York. The Institute is a member of the prestigious National Comprehensive Cancer Network, an alliance of the nation's leading cancer centers; maintains affiliate sites; and is a partner in national and international collaborative programs. For more information, visit <http://www.roswellpark.org>, call 1-877-ASK-RPCI (1-877-275-7724) or email [askrpci\(at\) roswellpark\(dot\)org](mailto:askrpci@roswellpark.org). Follow Roswell Park on Facebook and Twitter.

#